AxioMx Inc. Develops Novel Synthetic Antibody Library
Posted on Oct 6, 2014
Leader in recombinant antibody technologies successfully completes research that will lead to antibody reagent development times of less than four weeks.
BRANFORD, Conn. – October 6, 2014 – AxioMx Inc., a leader in recombinant antibody technologies, today announced the successful completion of research funded by a National Institute of Health (NIH) SBIR grant to develop a novel library for selection of affinity reagents. Under the research, AxioMx created a highly diverse synthetic phage-display antibody library.
“We are refining the affinity reagent discovery process to be cheaper and faster than currently possible, and to produce reagents that are more versatile and useful than current monoclonal antibodies,” said Christopher McLeod, president and CEO of AxioMx. “Our novel library has properties that facilitate both the initial affinity reagent selection and the subsequent maturation processes, which enables us to deliver a high-quality antibody for our customers more quickly.”
AxioMx is an early-stage biotechnology company that is developing a novel, high-throughput method to synthetically generate affinity reagents, which are fragments of monoclonal antibodies that specifically bind to target proteins and are useful in life science research, diagnostic tests and therapeutics. AxioMx’s goal is to reduce antibody reagent development time from the current four-to-six months (with traditional technology) to less than four weeks. AxioMx antibodies are generated entirely in vitro, which results in consistent antibody quality across production batches and does not involve the sacrifice of animals.
“Our new library virtually recapitulates the way antibodies are enriched in vivo in response to an antigen assault,” said Michael Weiner, Ph.D., co-founder and chief scientific officer of AxioMx. “But we can evaluate much larger recombinant libraries, in excess of 10 billion antibodies, that we can generate in vitro. Our new library format advances us closer to our goal of reducing antibody reagent development to less than four weeks and brings us one step closer to our vision of delivering custom antibodies in just days.”
This research was supported by the National Institute of General Medical Sciences of the NIH under Award Number R43GM105080. The content of this release is solely the responsibility of AxioMx and does not necessarily represent the official views of the National Institute of Health.About AxioMx Inc.
AxioMx, founded in 2012 and based in Branford, Connecticut, is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, Rapid Liquid Screening, and affinity maturation methods enables fast delivery of highly specific, high affinity, and reproducible recombinant antibodies that are optimized to work in a desired application. The company offers a full range of custom antibody discovery and development services for the research, diagnostic and therapeutic marketplaces. For more information on AxioMx, please visit www.axiomxinc.com.Download the Full Press Release